

ASX ANNOUNCEMENT

XanADu Patient Enrolment Advancing Towards Completion

- 75% of the total 174 patients now enrolled into Phase II XanADu clinical trial
- Addition of five new study sites in the US and partnership with dementia app developer, *MindMate*, expected to accelerate recruitment
- Enrolment projected to complete in Q4 2018
- Company on track to report top-line trial results in Q2 2019, less than 12 months from now

Sydney, 15 August 2018: Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to provide an update on patient enrolment into XanADu, its Phase II clinical trial of Xanamem in the treatment of mild Alzheimer's disease.

To date, 131 of the 174 patients, 75% of the total, have been enrolled and this achievement means that only 43 patients remain to be enrolled to complete the trial.

In July 2018, Actinogen announced the addition of five new study sites in the US. These new sites have already contributed to the trial, with a significant cohort of potential new patients screened and a number enrolled into the study.

Actinogen has also partnered with dementia app developer, *MindMate*, to identify potential eligible patients. *MindMate's* health and lifestyle app is used by over one million people worldwide who suffer from Alzheimer's disease, dementia, brain injury and other forms of cognitive decline.

The new study sites in the US and partnership with *MindMate*, along with a number of other initiatives, have helped enhance and accelerate the patient recruitment process. The Company remains on track to enrol the final patient by the end of this calendar year and expects to report the top-line trial data in the second quarter of 2019 – less than 12 months from now.

Actinogen Medical's CEO Dr Bill Ketelbey, said the Board was impressed with the progress made with patient recruitment across the study sites in the USA, Australia and the UK.

"The US has by far the largest potential patient population, and the addition of the new study sites in this region has provided positive impetus to patient recruitment. We're exceptionally pleased with the progress and look forward to completing enrolment later this year. This will move us one step closer to providing the top-line trial results in less than 12 months from now." Dr Bill Ketelbey said.

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

Media Enquiries

Imogen Conyers
Media & Capital Partners
M: +61 405 191 257
E: imogen.conyers@mcpartners.com.au

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.